Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H2 2018
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H2 2018
SUMMARY
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 19 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Coagulation Factor XI - Pipeline Review, H2 2018, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 5, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease which include indications Thrombosis, Bleeding And Clotting Disorders, Arterial Thrombosis, Hemophilia C (Factor XI Deficiency), Sepsis, Venous Thromboembolism, Acute Ischemic Stroke, Hemorrhagic Fever, Stroke and Venous (Vein) Thrombosis.
Furthermore, this report also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 19 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Coagulation Factor XI - Pipeline Review, H2 2018, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 5, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease which include indications Thrombosis, Bleeding And Clotting Disorders, Arterial Thrombosis, Hemophilia C (Factor XI Deficiency), Sepsis, Venous Thromboembolism, Acute Ischemic Stroke, Hemorrhagic Fever, Stroke and Venous (Vein) Thrombosis.
Furthermore, this report also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
- The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects
- The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Overview
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development
Bayer AG
Bio Products Laboratory Ltd
Bristol-Myers Squibb Co
Ionis Pharmaceuticals Inc
Mochida Pharmaceutical Co Ltd
Novartis AG
Sumitomo Dainippon Pharma Co Ltd
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles
AB-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1213790 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-262084 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-654457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-962212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSR-130787 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-7041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXILRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAA-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FXIa for Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Product Development Milestones
Featured News & Press Releases
Nov 13, 2017: eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
Jul 03, 2017: Bayer To Present Data on BAY 1213790 at ISTH 2017
Nov 01, 2016: Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Jul 04, 2016: MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
May 22, 2014: Cambryn Biologics Receives From FDA Orphan Drug Designation For Human Factor XI
Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma
Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding
Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders
Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Overview
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development
Bayer AG
Bio Products Laboratory Ltd
Bristol-Myers Squibb Co
Ionis Pharmaceuticals Inc
Mochida Pharmaceutical Co Ltd
Novartis AG
Sumitomo Dainippon Pharma Co Ltd
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles
AB-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1213790 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-262084 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-654457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-962212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSR-130787 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-7041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXILRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAA-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MR-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit FXIa for Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Product Development Milestones
Featured News & Press Releases
Nov 13, 2017: eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
Jul 03, 2017: Bayer To Present Data on BAY 1213790 at ISTH 2017
Nov 01, 2016: Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Jul 04, 2016: MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
May 22, 2014: Cambryn Biologics Receives From FDA Orphan Drug Designation For Human Factor XI
Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma
Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding
Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders
Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Bayer AG, H2 2018
Pipeline by Bio Products Laboratory Ltd, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Pipeline by Mochida Pharmaceutical Co Ltd, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018
Dormant Projects, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Bayer AG, H2 2018
Pipeline by Bio Products Laboratory Ltd, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Pipeline by Mochida Pharmaceutical Co Ltd, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018
Dormant Projects, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Bayer AG
Bio Products Laboratory Ltd
Bristol-Myers Squibb Co
Ionis Pharmaceuticals Inc
Mochida Pharmaceutical Co Ltd
Novartis AG
Sumitomo Dainippon Pharma Co Ltd
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Bayer AG
Bio Products Laboratory Ltd
Bristol-Myers Squibb Co
Ionis Pharmaceuticals Inc
Mochida Pharmaceutical Co Ltd
Novartis AG
Sumitomo Dainippon Pharma Co Ltd
